白介素1受体拮抗剂治疗骨关节炎的研究进展

骨关节炎（osteoarthritis, OA）是临床治疗中常见的骨科疾病，其主要以关节软骨变形、破坏及骨质增生为特征，目前没有根治手段。已有大量研究证明，白介素1（interleukin-1, IL-1）在OA病理进程中发挥关键作用，而IL-1受体拮抗剂（IL-1 receptor antagonist, IL-1Ra）已被证实可以竞争性地与IL-1受体结合，阻断IL-1的生物活性，从而抑制骨关节炎的进展，为OA治疗提供新的可能。本文将针对IL-1Ra在骨关节炎的治疗研究进展进行综述，围绕IL-1Ra介导的相关通路及其治疗骨关节炎的机理和策略进行总结，为OA治疗的研究和临床开发提供参考。

Research progress of interleukin-1 receptor antagonists in the treatment of osteoarthritis

Osteoarthritis(OA) is a common orthopedic disease in clinical treatment, which is mainly characterized by articular cartilage deformation, destruction and bone hyperplasia. Currently, there is no radical treatment. It has been proved that interleukin-1 (IL-1) plays an important role in the occurrence and development of osteoarthritis, and IL-1 receptor antagonist (IL-1Ra) has been confirmed to competitively bind to IL-1 receptor and block the biological activity of IL-1, thus inhibiting the progression of osteoarthritis. It provided new possibilities for OA treatment. This paper will review the research progress of IL-1Ra in the treatment of osteoarthritis, and summarize the related pathways mediated by IL-1Ra and its mechanism and strategy for the treatment of osteoarthritis, so as to provide reference for research and clinical development of osteoarthritis treatment.